PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling

References

• Alas S, Bonavida B. 2003. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 9(1):316–326.
   PubMed Web of Science ®Google Scholar
• Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. 2005. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65(12):5054–5062.
   PubMed Web of Science ®Google Scholar
• Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, et al. 2018. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. JAMA Oncol. 4(10):1405–1409.
   PubMed Web of Science ®Google Scholar
• Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M. 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 99(1):252–257.
   PubMed Web of Science ®Google Scholar
• Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M. 2010. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol. 100(3):339–343.
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Molenaar RJ, Leenstra S. 2012. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 108(1):11–27.
   PubMed Web of Science ®Google Scholar
• Bourgonje AM, Verrijp K, Schepens JT, Navis AC, Piepers JA, Palmen CB, van den Eijnden M, Hooft van Huijsduijnen R, Wesseling P, Leenders WP, et al. 2016. Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathol Commun. 4(1):96–109.
   PubMedGoogle Scholar
• Gallego O. 2015. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 22(4):e273–e281.
   PubMed Web of Science ®Google Scholar
• Germain D, Frank D. 2007. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 13(19):5665–5669.
   PubMed Web of Science ®Google Scholar
• Han S, Khuri FR, Roman J. 2006. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 66(1):315–323.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. 2004. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 10(6):1871–1874.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352(10):997–1003.
   PubMed Web of Science ®Google Scholar
• Im JY, Kim BK, Lee KW, Chun SY, Kang MJ, Won M. 2020. DDIAS promotes STAT3 activation by preventing STAT3 recruitment to PTPRM in lung cancer cells. Oncogenesis. 9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Johnson DR, O’Neill BP. 2012. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 107(2):359–364.
   PubMed Web of Science ®Google Scholar
• Kirstein A, Schmid TE, Combs SE. 2020. The Role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme. Cancers. 12(5):1099–1121.
   PubMed Web of Science ®Google Scholar
• Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, et al. 2015. Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci USA. 112(30):E4055–E4064.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang C, Liao Y, Liu J, Huang J, Xia M, Chen M, Tan H, He W, Xu M, et al. 2020. High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer. Cell Death Dis. 11(8):687–703.
   PubMed Web of Science ®Google Scholar
• Long H, Liang C, Zhang X, Fang L, Wang G, Qi S, Huo H, Song Y. 2017. Prediction and analysis of key genes in glioblastoma based on bioinformatics. Biomed Res Int. 2017:7653101–7653107.
   PubMed Web of Science ®Google Scholar
• Mao Y, Schwarzbauer JE. 2005. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 24(6):389–399.
   PubMed Web of Science ®Google Scholar
• Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D, Hammack J, Ortiz K, Lesser E, et al. 2020. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol. 147(2):297–307.
   PubMed Web of Science ®Google Scholar
• Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK, Pan E, Aliwarga E, Chong ST, Kok CYL, et al. 2017. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat Commun. 8(1):1913–1929.
   PubMedGoogle Scholar
• Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. 2014. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 16(4):1–63.
   PubMedGoogle Scholar
• Pereira IT, Ramos EA, Costa ET, Camargo AA, Manica GC, Klassen LM, Chequin A, Braun-Prado K, Pedrosa Fde O, Souza EM, et al. 2014. Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines. PLoS One. 9(9):e105806.
   PubMed Web of Science ®Google Scholar
• Roman MG, Flores LC, Cunningham GM, Cheng C, Dube S, Allen C, Remmen HV, Bai Y, Hubbard GB, Saunders TL, et al. 2020. Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice. Aging Pathobiol Therap. 2(1):20–31.
   PubMedGoogle Scholar
• Stevenson WS, Best OG, Przybylla A, Chen Q, Singh N, Koleth M, Pierce S, Kennedy T, Tong W, Kuang SQ, et al. 2014. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia. 28(4):787–793.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Thaler R, Karlic H, Spitzer S, Klaushofer K, Varga F. 2010. Extra-cellular matrix suppresses expression of the apoptosis mediator Fas by epigenetic DNA methylation. Apoptosis. 15(6):728–737.
   PubMed Web of Science ®Google Scholar
• Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 7(11):833–846.
   PubMed Web of Science ®Google Scholar
• Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò A, Granato T, De Vincenzi B, Coppotelli G, et al. 2005. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int J Oncol. 27(4):1005–1011.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang J, Wang H, Wang W, Liang X. 2020. Highly expressed ribosomal protein L34 predicts poor prognosis in acute myeloid leukemia and could be a poential therapy target. Aging Pathobiol Therap. 2(1):32–37.
   Google Scholar
• Williams C, Engler A, Slone R, Galante L, Schwarzbauer J. 2008. Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res. 68(9):3185–3192.
   PubMed Web of Science ®Google Scholar
• Xu K, Xu Q, Wu Z, Xu S, Shen J. 2018. LncRNA NEAT1 is involved in temozolomide resistance by regulating MGMT in glioblastoma multiforme. Clin Surg Res Commun. 2(1):24–30.
   Google Scholar
• Yang CH, Wang Y, Sims M, Cai C, Pfeffer LM. 2019. MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin. Cancer Lett. 465:59–67.
   PubMed Web of Science ®Google Scholar
• Yang J, Shi Z, Liu R, Wu Y, Zhang X. 2020. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics. 10(7):3223–3239.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang Q, Huang XM, Liao DZ. 2020. Circular RNA circCNOT6L regulates cell development through modulating miR-384/FN1 axis in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 24(7):3674–3685.
   PubMed Web of Science ®Google Scholar